New PhD, Marianne L. Smebye, found RNA changes involved in ovarian cancer

Marianne L. Smebye
Marianne L. Smebye
As part of a long-term collaboration between the Section for Cancer Cytogenetics at the Institute for Medical Informatics and Section for Molecular Oncology at the Institute for Cancer Research, a joint PhD project has been carried out to study RNA changes in ovarian cancer.

The PhD work concluded on March 17th, when Cand. med. Marianne Lislerud Smebye successfully defended her thesis "Transcriptomic consequences of chromosome 19 rearrangements in ovarian carcinomas" for the PhD degree. The same day, she held an excellent trial lecture over the given topic "Chromosomal abnormalities and copy number rearrangements as clinical targets in cancer". The PhD work was jointly surpervised between Francesca Micci (main supervisor), Sverre Heim and Rolf Skotheim.


A retrospective pooled biomarker study to predict overall survival beyond the TNM system

Researchers Stine Aske Danielsen and Anita Sveen.
Researchers Stine Aske Danielsen and Anita Sveen.

K.G.Jebsen Colorectal Cancer Research Centre scientists participated with data from patients admitted to OUH in a multicenter study of >7000 stage II and III CRC recently reported in Annals of Oncology (Dienstmann et al).
Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.


POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis

Ragnhild A. Lothe and Arild Nesbakken
Ragnhild A. Lothe and Arild Nesbakken

A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G.Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
A small subgroup of patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading are shown to have excellent prognosis.


The Norwegian Cancer Society calls attention to collaborative study on relevance of genetic heterogeneity

Anita Sveen is heavily involved in the study (photo Terje Heiestad)

The Norwegian Cancer Society has recently presented a research project on their home page where researchers from Oslo and Bergen have performed genetic analyses on cancer cells that have spread from the gut to the liver. The results show that the degree of genetic heterogenenity between the tumors in the gut and in the liver respectively may reveal important prognostic information. The study led by Ragnhild A. Lothe from the Department of Moleceular Oncology at OUS and Per Eystein Lønning from Haukeland University Hospital.


Clinical relevance of genetic heterogeneity among distinct liver metastatic deposits identified in patients with colorectal cancer

Anita Sveen (first author)
Anita Sveen (first author)

In this collaborative study with Dept Oncology, Haukeland University Hospital and Dept Computer Science, University of Oslo, scientist Anita Sveen (photo) and colleagues in the Lothe group show that patients with a low level of heterogeneity, based on DNA copy number analyses of multiple metastases per patient, have a 4.6X and 3.6X longer three-year progression free and overall survival rate than patients with a high heterogeneity level.


Article on colorectal cancer research at


Researchers from Department of Molecular Oncology profiled in a recent article on colorectal cancer at


Post doc Jarle Bruun awarded excellent article from Oslo University Hospital for the second half of 2015

Award winners of excellent article prize

In order to stimulate excellent research and draw attention to the hospital's extensive research activity, Oslo University Hospital reward outstanding publications regularly.

Six research groups were awarded for their excellent papers published during the second half-year of 2015 during a ceremony June 17th. Each group was given NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.

Every half-year, six of the very best papers authored by scientists working on the hospital (first or last author must be affiliated to OUS) are selected. The nomination takes place through the research panel of each division. The final selection process is performed by an external committee.


Losby III 10.-11. mars 2016

National conference on clinical genomics

S. Smeland
S. Smeland

The National conference on clinical genomics at Losby is arranged for the third time by professors Ragnhild A. Lothe and Per Eystein Lønning on behalf of the National priority area – Cancer (“Nasjonal kreftsatsing”).
The opening address will be given by the Head of the Cancer Clinic, professor Sigbjørn Smeland (photo).
Oncologists, scientists and leaders are gathered to discuss the need and challenges of new cancer treatments. Key note speaker Dr. Rodrigo Dienstmann, Vall D’Hebron institute, Barcelona, will give the following talk: ”Paradigm shifts in Precision Medicine: Colorectal Cancer as a Model”


Ragnhild A. Lothe and Michael Bretthauer substantially supported by FRIPRO

Lothe and Bretthauer
Lothe and Bretthauer

The Research Council of Norway and Norway’s research institutions are providing a total of NOK 1 billion to 46 FRIPRO Toppforsk projects (FRIPRO - "Frie prosjektmidler"). Each project will receive NOK 15–25 million over a four-to-five-year period.
FRIPRO is an open competitive arena for all research areas and disciplines, where there are no thematic guidelines and no requirements relating to the applicability or immediate utility of the research. The competition in FRIPRO is tough, and only the best researchers with particularly good projects and very well-written proposals have a chance at succeeding.
University of Oslo and Oslo University Hospital based research groups led by Ragnhild A. Lothe from the Department of Molecular Oncology and Michael Bretthauer from the Department of Transplantation Medicine are among the successful applicants. 


New PhD Andreas Hoff publishes testis cancer fusion genes in Cancer Research

Andreas M. Hoff
Andreas M. Hoff

Andreas Midbøe Hoff, who recently defended his PhD thesis, has together with colleagues at Department of Molecular Oncology discovered novel fusion genes in testicular germ cell tumours. The results are published in the current issue of Cancer Research (journal impact factor 9.28)


Previous news
 Ragnar Mørk legacy prize 2015 to Guro E. Lind Ceremony Friday November 20th 
 Group leader Guro E. Lind appointed leader of the newly established Young Academy of Norway  
 Review article in Oncogene on alternative splicing in cancer  
 Personalized cancer medicine. Chronicle in the Norwegian newspaper, Aftenposten  
 Interview in weekly magazine on big data in cancer biomedicine  
 Cover article on personalized cancer medicine and big data in META  
 Many OUS teams in the Holmenkollstafetten 2015 Public health improvement: 
 Novel DNA methylation biomarkers provide accurate detection of bile duct cancer  
 Supercomputing reveals the genetic code of cancer Rolf Skotheim interview in Apollon: 
 Masterstudent Heidi Pharo graduated from the Department of Cancer Prevention  
 New comprehensive review on PI3K signaling in colorectal cancer  
 SMART Colorectal Cancer featured in Norwegian patient safety publication  
 Movember: Team Cancer Prevention  
 Oslo University Hospital awarding excellent research  
 Official opening of the KG Jebsen Colorectal Cancer Research Centre  
 Department of Cancer Prevention held a public cancer research event for the Røst community  
 Two new PhDs  
 Marthe Løvf defended her thesis for the PhD degree  
 Successful cancer genomics conference at Losby followed up by national media  
 New K.G. Jebsen Center for colorectal cancer research led by Ragnhild A. Lothe  
 Bioinformatician Torfinn Nome defending PhD thesis on deep RNA sequencing of colorectal cancer  
 Comprehensive review free online  
 Publication in Nature Genetics on testicular cancer susceptibility  
 PhD student Deeqa Ahmed profiled in Uniforum  
 Research based innovation  
 Comprehensive review on molecular biology of germ cell tumors of the ovary  
 Group leader Guro E. Lind invited to Ekko, NRK P2  
 Ragnhild A. Lothe appointed "Innovator of the month" by Helse Sør-Øst for March 2013  
 Alagaratnam article published in Stem Cells and Development  
 Breaking advances in prognostic testing of colorectal cancer  
 New group in Epigenetics established at the Institute for Cancer Research, Dept of Cancer Prevention  
 Ragnhild A. Lothe selected Scientist of the Month  
 ColoGuideEx receives attention  
 Anita Sveen and Trude Holmeide Ågesen successfully defended their PhD theses  
 British biotech company signs agreement with Inven2 to secure exclusive rights to biomarkers identified in the Lothe group  
 New gene-based prognostic test for colorectal cancer  
 The Norwegian Oncology Forum’s Young Researcher award 2011 to Guro E. Lind  
 Stine Aske Danielsen successfully defends her PhD thesis  
 Andreas Hoff and Peter Eide awarded Master’s degree  
 Researchers from Department of Cancer Prevention reveal importance for transcriptome instability in colorectal cancer  
 Ragnhild A. Lothe elected to the EACR Council  
 Marianne Berg - Excellent trial lecture for PhD  
 Maren Høland graduated  
 Forskning om nerveskjedesvulster omtalt på forskningsrådets hjemmeside  
 Translational research on colorectal cancer within Oslo University hospital featured in Dagbladet newspaper  
 Molecular Genetics group publishes in Journal of Clinical Oncology  
 MSc degree to Anne Cathrine Bakken  
 Dr. Ragnar Mørk legacy prize 2009 to Rolf I. Skotheim  
 The biomarker project in Aftenposten  
 Interview with Guro Lind in Apollon  
 Disputation and trial lecture - Terje Cruickshank Ahlquist  
 Stine Danielsen awarded poster prize at the 30th Scandinavian Sarcoma Group Meeting  
 Mutations in the Neurofibromin gene, an inhibitor of KRAS  
 New microarray design for detection of fusion genes  
 Ahlquist and colleagues identify time of occurrence of specific methylation events in colorectal development.  
 Marthe Eken graduated  
 Interview with Ragnhild Lothe on national television [in Norwegian]  
 Skotheim - First runner up to Idea Prize 2008  
 Young Investigator Award to Rolf Skotheim  
 Invited speaker at Biomarker Discovery Conference  
 Dietary effects on genes - National Broadcasting Company  
 In thin air - The annual mountain trip  
 ”Signaling in colorectal cancer”. Two recent papers by PhD students Stine A. Danielsen and Terje Ahlquist and colleagues  
 On the road again  
 Interview with Guro E. Lind in Universitas  
 Cancer Prevention - on thin ice...  
 State visit to Portugal, May 2008.  
 Master student Hilde Honne graduated  
 Masterstudenter intervjuet  
 What is epigentics? - National Broadcasting Company  
 Medinnova Idea Prize 2007 - presentation in Onkonytt  
 Rolf I. Skotheim appointed visiting professor in Finland  
 Medinnova's Idea Prize to research group working on early markers for tumors in the digestive system  
 Edgar Rivedal elected member of scientific council of IARC  
 Ragnhild A Lothe awarded the "King Olav V's Cancer Research Award"  
 King Olav V’s prize for cancer research 2007 awarded to Ragnhild A. Lothe  
 Center for Cancer Biomedicine funded  
 New cancer review journal edited at RR-Medical Centre: Critical Reviews in Oncogenesis  
 Porto – Oslo collaboration publishes improved prognostication by genetic analyses of prostate cancer  
 CoE-applicant from the Institute for cancer research to final round  
 New Department  
 Lothe group participant in a new Centre of Sciencebased Innovation  
 New data from an international collaborative study on TP53 and colorectal cancer, including data from the Lothe lab  
 Kristine Kleivi interviewed by the Norwegian Cancer Society  
 Ragnhild Lothe new member of the Commission for Forensic Medicine  
 Funding provided by Helse Sør  
 Disputation and trial lecture - Kristine Kleivi  
 Disputation and trial lecture - Guro E. Lind  
 Cover article in Neoplasia by Lin Thorstensen and coworkers. February 2005.  
 Ragnhild Lothe's group supported from National Cancer Plan